Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.5900+0.0400 (+0.88%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.5500
Open4.4600
Bid0.0000 x 1300
Ask0.0000 x 900
Day's range4.4600 - 4.6500
52-week range1.3720 - 16.8000
Volume18,411
Avg. volume41,638
Market cap15.345M
Beta (5Y monthly)0.42
PE ratio (TTM)N/A
EPS (TTM)-2.9850
Earnings date06 Mar 2023 - 10 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est63.50
  • GlobeNewswire

    Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

    Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case FiledSOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that a joint stipulation of dismissal has been filed in the GIMOTI® patent infringement case (Civil Action No. 1:22-cv-02019) in the Uni

  • GlobeNewswire

    Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

    Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTISOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its abstract entitled “Real-World Healthcare Resource Utilization of Patients Treated with Metoclo

  • GlobeNewswire

    USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

    SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.” This patent expires in 2038 and covers the methods for treating moderate-to-